Suppression of Fgfr3 signaling by inhibition of Fgfr3 or phosphorylation of the downstream effectors improved cartilage growth in vitro and pathological characteristics of slc26a2−/− newborn mice [28], suggesting that this could be another treatment target in DTD. The gene discussed is FGFR3; the disease is diastrophic dysplasia.